Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.
Publication
, Journal Article
Lyman, GH; Henk, HJ
Published in: JAMA Oncol
December 1, 2020
This cohort study identifies trends in tyrosine kinase inhibitor use in patients with chronic myelogenous leukemia and the association those treatment choices have with health care costs.
Duke Scholars
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
December 1, 2020
Volume
6
Issue
12
Start / End Page
1969 / 1971
Location
United States
Related Subject Headings
- Protein Kinase Inhibitors
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Imatinib Mesylate
- Humans
- Drugs, Generic
- Costs and Cost Analysis
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Henk, H. J. (2020). Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia. JAMA Oncol, 6(12), 1969–1971. https://doi.org/10.1001/jamaoncol.2020.4660
Lyman, Gary H., and Henry J. Henk. “Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.” JAMA Oncol 6, no. 12 (December 1, 2020): 1969–71. https://doi.org/10.1001/jamaoncol.2020.4660.
Lyman GH, Henk HJ. Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia. JAMA Oncol. 2020 Dec 1;6(12):1969–71.
Lyman, Gary H., and Henry J. Henk. “Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.” JAMA Oncol, vol. 6, no. 12, Dec. 2020, pp. 1969–71. Pubmed, doi:10.1001/jamaoncol.2020.4660.
Lyman GH, Henk HJ. Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia. JAMA Oncol. 2020 Dec 1;6(12):1969–1971.
Published In
JAMA Oncol
DOI
EISSN
2374-2445
Publication Date
December 1, 2020
Volume
6
Issue
12
Start / End Page
1969 / 1971
Location
United States
Related Subject Headings
- Protein Kinase Inhibitors
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Imatinib Mesylate
- Humans
- Drugs, Generic
- Costs and Cost Analysis
- Antineoplastic Agents
- 3211 Oncology and carcinogenesis
- 1117 Public Health and Health Services
- 1112 Oncology and Carcinogenesis